News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
92,638 Results
Type
Article (6731)
Company Profile (39)
Press Release (85868)
Section
Business (27712)
Career Advice (127)
Deals (3989)
Drug Delivery (32)
Drug Development (14116)
Employer Resources (12)
FDA (2847)
Job Trends (2111)
News (49198)
Policy (6004)
Tag
2024 BioForest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
2026 Pharm Country Premier (1)
Academia (425)
Accelerated approval (1)
Adcomms (7)
Allergies (30)
Alliances (8993)
ALS (13)
Alzheimer's disease (257)
Antibody-drug conjugate (ADC) (38)
Approvals (2852)
Artificial intelligence (37)
Autoimmune disease (7)
Automation (3)
Bankruptcy (19)
Best Places to Work (1797)
BIOSECURE Act (16)
Biosimilars (73)
Biotechnology (26)
Bladder cancer (20)
Brain cancer (6)
Breast cancer (50)
Cancer (424)
Cardiovascular disease (19)
Career advice (110)
Career pathing (3)
CAR-T (20)
Cell therapy (81)
Cervical cancer (3)
Clinical research (11488)
Collaboration (177)
Compensation (40)
Complete response letters (9)
COVID-19 (544)
CRISPR (4)
C-suite (45)
Cystic fibrosis (13)
Data (396)
Denatured (2)
Depression (4)
Diabetes (35)
Diagnostics (556)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (22)
Drug pricing (22)
Drug shortages (1)
Duchenne muscular dystrophy (24)
Earnings (9453)
Editorial (5)
Employer branding (3)
Employer resources (10)
Events (11792)
Executive appointments (107)
FDA (3165)
Featured Employer (9)
Frontotemporal dementia (1)
Funding (139)
Gene editing (22)
Generative AI (5)
Gene therapy (77)
GLP-1 (107)
Government (1305)
Grass and pollen (1)
Guidances (11)
Healthcare (1950)
Huntington's disease (2)
IgA nephropathy (1)
Immunology and inflammation (36)
Indications (8)
Infectious disease (576)
Inflammatory bowel disease (46)
Inflation Reduction Act (4)
Influenza (15)
Intellectual property (11)
Interviews (11)
IPO (1834)
IRA (13)
Job creations (385)
Job search strategy (107)
Kidney cancer (2)
Labor market (2)
Layoffs (53)
Legal (557)
Liver cancer (13)
Lung cancer (73)
Lymphoma (25)
Management (2)
Manufacturing (99)
MASH (9)
Medical device (1166)
Medtech (1167)
Mergers & acquisitions (2245)
Metabolic disorders (81)
Multiple sclerosis (15)
NASH (2)
Neurodegenerative disease (16)
Neuropsychiatric disorders (1)
Neuroscience (324)
NextGen: Class of 2025 (696)
Non-profit (348)
Northern California (451)
Now hiring (10)
Obesity (30)
Opinion (45)
Ovarian cancer (20)
Pain (8)
Pancreatic cancer (13)
Parkinson's disease (9)
Partnered (3)
Patents (28)
Patient recruitment (19)
Peanut (21)
People (7961)
Pharmaceutical (11)
Pharmacy benefit managers (2)
Phase I (3779)
Phase II (4781)
Phase III (4211)
Pipeline (259)
Podcasts (6)
Policy (36)
Postmarket research (297)
Preclinical (1474)
Press Release (66)
Prostate cancer (15)
Psychedelics (5)
Radiopharmaceuticals (35)
Rare diseases (67)
Real estate (916)
Recruiting (4)
Regulatory (4749)
Reports (11)
Research institute (386)
Resumes & cover letters (11)
RNA editing (1)
RSV (9)
Schizophrenia (11)
Series A (32)
Series B (13)
Service/supplier (3)
Sickle cell disease (7)
Southern California (458)
Special edition (3)
Spinal muscular atrophy (21)
Sponsored (9)
Startups (574)
State (1)
Stomach cancer (3)
Supply chain (9)
The Weekly (4)
United States (3906)
Vaccines (177)
Venture capitalists (4)
Webinars (1)
Weight loss (14)
Women's health (3)
Date
Today (29)
Last 7 days (142)
Last 30 days (560)
Last 365 days (6345)
2025 (1531)
2024 (6509)
2023 (6962)
2022 (9056)
2021 (9473)
2020 (8172)
2019 (5837)
2018 (4510)
2017 (5058)
2016 (4617)
2015 (5269)
2014 (3717)
2013 (2892)
2012 (2985)
2011 (3146)
2010 (2572)
Location
Africa (92)
Alabama (11)
Alaska (1)
Arizona (12)
Arkansas (2)
Asia (7481)
Australia (881)
California (1076)
Canada (223)
China (163)
Colorado (32)
Connecticut (25)
Delaware (36)
Europe (13806)
Florida (126)
Georgia (18)
Idaho (13)
Illinois (44)
India (11)
Indiana (39)
Iowa (1)
Japan (26)
Kansas (3)
Kentucky (9)
Louisiana (2)
Maine (5)
Maryland (311)
Massachusetts (731)
Michigan (23)
Minnesota (44)
Mississippi (1)
Missouri (14)
Montana (5)
Nebraska (1)
Nevada (4)
New Hampshire (3)
New Jersey (429)
New Mexico (4)
New York (297)
North Carolina (192)
North Dakota (7)
Northern California (451)
Ohio (39)
Oklahoma (7)
Oregon (2)
Pennsylvania (181)
Puerto Rico (1)
Rhode Island (5)
South America (134)
South Carolina (2)
Southern California (458)
Tennessee (3)
Texas (136)
Utah (23)
Virginia (15)
Washington D.C. (6)
Washington State (86)
Wisconsin (7)
92,638 Results for "gensight biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025
March 17, 2025
·
4 min read
Press Releases
GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates
March 20, 2025
·
11 min read
Press Releases
GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results
February 27, 2025
·
18 min read
Policy
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
GenSight Biologics announced the renegotiation of certain financial obligations, securing its financial position and improving short-term flexibility.
June 20, 2024
·
6 min read
Press Releases
GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update
January 23, 2025
·
5 min read
Press Releases
GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation
December 19, 2024
·
3 min read
Press Releases
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
February 12, 2025
·
9 min read
Policy
GenSight Biologics Announces its 2024 Financial Calendar
GenSight Biologics today announced its financial calendar for 2024.
April 4, 2024
·
1 min read
Business
GenSight Biologics Appoints William Monteith to its Board of Directors
GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the appointment of William Monteith to its Board of Directors.
June 3, 2024
·
4 min read
Press Releases
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy
January 15, 2025
·
8 min read
1 of 9,264
Next
